Amivantamab for Exon 20-Related NSCLC: Excitement in the Patient Community We look forward to Dr. Joshua Sabari’s presentation during the oral abstract presentation session “OA04: new Data from Rare EGFR […] Read more
The abstract “Patient-reported outcomes from the randomized Phase 3 CROWN study of first-line lorlatinib versus crizotinib in ALK+ NSCLC” by Mazieres et al., presents a welcome analysis of symptoms and […] Read more
Palliative and end of life care discussions are significant and essential, yet sensitive and challenging. Cultural perceptions of pain and end of life can filter nuances in provider communication in […] Read more
Whole-exome sequencing reveals that almost half of all patients with small cell lung cancer (SCLC) have a deleterious germline mutation which may be associated with the development of their disease […] Read more
Read the full articles for detailed summaries of each presentation. TALENT: This national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in […] Read more
Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has […] Read more
Mobocertinib for Exon 20-Related Lung Cancer of Great Interest to Patients My brother Kevin, who founded the Exon 20 Group at ICAN with me in early 2017, started on mobocertinib […] Read more
Between 60% and 65% of patients with lung cancer receive their diagnoses at stage III or IV, meaning that one-third are unaware of their disease when radical surgery, either alone […] Read more
Combined treatment with lurbinectedin and irinotecan appears to pack quite a punch in patients with relapsed small cell lung cancer (SCLC) according to the results of a phase Ib/II trial […] Read more
New insights into the types of EGFR mutations that can arise in NSCLC may help guide decisions about the most appropriate targeted drugs for individual patients. A study by Jacqulyne […] Read more